Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Catalyst Pharmaceutical Partners has filed US provisional patent application for the use of GABA aminotransferase inhibitors, including CPP-109 and CPP-115, in the treatment of Tourette Syndrome.
Subscribe to our email newsletter
Catalyst’s intellectual property is a method of treating Tourette Syndrome using GABA aminotransferase inhibitor drugs, including CPP-109 and CPP-115.
The method increases presynaptically stored GABA, and enhance GABA signaling in the striatal-thalamo-cortical tracts involved in habit formation and motor control.
Catalyst CEO Patrick McEnany said the use of CPP-109 and CPP-115 in the treatment of Tourette Syndrome may provide them with significant CNS expansion opportunities while addressing an important medical need.